Related Experiment Videos
Placental-type plasminogen activator inhibitor in preeclampsia
K de Boer1, I Lecander, J W ten Cate
1Division of Haemostasis and Thrombosis, Academisch Medisch Centrum, Amsterdam, The Netherlands.
Insights
In preeclampsia, total plasminogen activator inhibitor is high, but placental-type plasminogen activator inhibitor is low, suggesting it doesn't cause increased activity. Low placental-type plasminogen activator inhibitor may indicate poor fetal outcomes.
Area of Science:
- Obstetrics and Gynecology
- Reproductive Biology
- Hematology
Background:
- Preeclampsia and gestational hypertension are significant pregnancy complications.
- The fibrinolytic system plays a crucial role in pregnancy physiology and pathology.
- Imbalances in fibrinolytic factors are implicated in hypertensive disorders of pregnancy.
Purpose of the Study:
- To investigate the role of the fibrinolytic system, specifically plasminogen activator inhibitors, in preeclampsia and gestational hypertension.
- To compare levels of total and placental-type plasminogen activator inhibitor in patients versus controls.
- To explore the association of placental-type plasminogen activator inhibitor with fetal outcomes and placental function.
Main Methods:
- Cross-sectional study design.
- Inclusion of patients with preeclampsia, gestational hypertension, and gestational age-matched controls.
- Measurement of total plasminogen activator inhibitor and placental-type plasminogen activator inhibitor levels.
Main Results:
- Preeclampsia patients exhibited elevated total plasminogen activator inhibitor levels compared to controls.
- Preeclampsia patients showed reduced placental-type plasminogen activator inhibitor levels.
- Significantly lower placental-type plasminogen activator inhibitor levels were observed in pregnancies with poor fetal outcomes.
- Placental-type plasminogen activator inhibitor levels correlated with birth weight and placenta weight.
Conclusions:
- Placental-type plasminogen activator inhibitor does not account for the increased total plasminogen activator inhibitor activity in preeclampsia.
- Reduced placental-type plasminogen activator inhibitor may serve as a marker for impaired placental function and adverse fetal outcomes.
- Further research into the fibrinolytic system's role in hypertensive disorders of pregnancy is warranted.
Abstract:
The present cross-sectional study in patients with preeclampsia and gestational hypertension and in gestational age-matched controls was undertaken to investigate further the fibrinolytic system in these conditions. In preeclampsia we observed increased levels of total plasminogen activator inhibitor (p less than 0.001) but low levels of placental-type plasminogen activator inhibitor (p less than 0.05) compared with controls. The levels of placental-type plasminogen activator inhibitor were even more reduced (p less than 0.002) in pregnancies with a poor fetal outcome. It is concluded that placental-type plasminogen activator inhibitor does not contribute to the increased levels of total plasminogen activator inhibitor activity in preeclampsia. Placental-type plasminogen activator inhibitor levels correlated significantly with birth weight and placenta weight and may therefore reflect placental function.